Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker UPTD, is a clinical-stage biopharmaceutical company operating in the immunotherapy sector that reached public markets through a SPAC business combination. The company filed a Form 10-Q with the Securities and Exchange Commission on August 1, 2023, reporting quarterly results as a post-merger public entity. Estrella's pipeline targets immunological and oncological indications, positioning it within the life sciences segment of the de-SPAC landscape. The filing, carrying accession number 0001213900-23-061563, reflects the company's ongoing public reporting obligations following its SPAC transaction. For complete deal history, sponsor details, filing timelines, and real-time analytics on UPTD and hundreds of other SPAC vehicles, sign up for full data access at SpacDesk.